Meropenem antimicrobial stewardship program: clinical, economic, and antibiotic resistance impact
There are few prospective studies with sufficient duration in time to evaluate clinical and antibiotic resistance impact of antibiotic stewardship programs (ASP). This is a descriptive study between January 2012 and December 2017, pre-post intervention. A meropenem ASP was initiated in January 2015; in patients who started treatment with meropenem, an infectious disease physician performed treatment recommendations to prescribers. Prospective information was collected to evaluate adequacy of meropenem prescription to local guidelines and to compare results between cases with accepted or rejected intervention. Analysis was performed to verify variables associated with intervention acceptance and with any significant change in meropenem consumption, hospital-acquired multidrug-resistant (MDR) bloodstream infections (BSIs), and 30-day all-cause crude death in MDR BSIs. Adequacy of meropenem prescription and de-escalation from meropenem treatment to narrower-spectrum antibiotic improved progressively over time, after ASP implementation (p < 0.001). Interventions on prescription were performed in 330 (38.7%) patients without meropenem justified treatment; in 269, intervention was accepted and in 61 not. Intervention acceptance was associated with shorter duration of treatment, cost, and inpatient days (p < 0.05); intervention rejection was not associated with severity of patient. During the period 2015–2017, meropenem consumption decreased compared with 2012–2014 (rate ratio [RR] 0.67; 95% CI 0.58–0.77, p < 0.001). Also decreased were hospital-acquired MDR BSI rate (RR 0.63; 95% CI 0.38–1.02, p = 0,048) and 30-day all-cause crude death in MDR BSIs (RR 0.45; 95% CI 0.14–1.24, p = 0.096), coinciding in time with ASP start-up. The decrease and better use of meropenem achieved had a sustained clinical, economic, and ecological impact, reducing costs and mortality of hospital-acquired MDR BSIs.
KeywordsAntimicrobial stewardship Multidrug-resistant Hospital infections Bloodstream infections Carbapenems
The authors acknowledge the Clinical Epidemiology and Biostatistics Unit of the Complejo Hospitalario Universitario A Coruña and the Spanish Platform for Clinical Research and Clinical Trials, SCReN (Spanish Clinical Research Network), for their assistance in methodological design and statistical analysis.
Compliance with ethical standards
The authors declare that they have no competing interests.
- 1.United Nations (2017) General Assembly of the United Nations: President of the 71st Session. 2016. http://www.un.org/pga/71/2016/09/21/press-release-hl-meeting-on-antimicrobial-resistance/ (accesed Nov 21, 2007)
- 4.ECDC (2017) Summary of the latest data on antibiotic consumption in the European Union. https://ecdc.europa.eu/sites/portal/files/documents/Final_2017_EAAD_ESAC-Net_Summary-edited%20-%20FINALwith%20erratum.pdf. (accessed Feb 28, 2018)
- 6.Lawes T, López-Lozano JM, Nebot CA, Macartney G, Subbarao-Sharma R, Dare CRJ et al (2015) Effects of national antibiotic stewardship and infection control strategies on hospital-associated and community-associated meticillin-resistant Staphylococcus aureus infections across a region of Scotland: a non-linear time-series study. Lancet Infect Dis 15:1438–1449CrossRefGoogle Scholar
- 7.Akpan MR, Ahmad R, Shebl NA, Ashiru-Oredope D (2016) A review of quality measures for assessing the impact of antimicrobial stewardship programs in hospitals. Antibiotics 5(1):5. https://doi.org/10.3390/antibiotics5010005
- 8.Molina J, Peñalva G, Gil-Navarro MV, Praena J, Lepe JA, Pérez-Moreno MA et al (2017) Long-term impact of an educational antimicrobial stewardship program on hospital-acquired candidemia and multidrug-resistant bloodstream infections: a quasi-experimental study of interrupted time-series analysis. Clin Infect Dis 65(12):1992–1999Google Scholar
- 11.Baur D, Gladstone BP, Burkert F, Carrara E, Foschi F, Döbele S, Tacconelli E (2017) Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis. Lancet Infect Dis 17(9):990–1001CrossRefGoogle Scholar
- 12.García-Rodríguez JF, Álvarez-Díaz H, Vilariño-Maneiro L, Lorenzo-García MV, Cantón-Blanco A, Ordoñez-Barrosa P et al (2013) Epidemiology and impact of a multifaceted approach in controlling central venous catheter associated blood stream infections outside the intensive care unit. BMC Infect Dis 13:445 http://www.biomedcentral.com/1471-2334/13/445. (Accessed Feb 8, 2018CrossRefGoogle Scholar
- 14.WHO Collaborating Center for Drug Statistics Methodology (2016). DDD definition and general considerations.. Available from: https://www.whocc.no/ddd/definition_and_general_considera/. (Accessed Feb 8, 2018)
- 15.Mattner F, Bange FC, Meyer E, Seifert H, Wichelhaus TA, Chaberny IF (2012) Preventing the spread of multidrug-resistant gram-negative pathogens: recommendations of an expert panel of the German Society For Hygiene and Microbiology. Dtsch Arztebl Int 109(3):39–45Google Scholar
- 17.Moehring RW, Anderson DJ, Cochran RL, Hicks LA, Srinivasan A, Ashley ESD (2017) For the Structured Taskforce of Experts Working at Reliable Standards for Stewardship (STEWARDS) Panel. Expert consensus on metrics to assess the impact of patient-level antimicrobial stewardship interventions in acute-care settings. Clin Infect Dis 64(3):377–383CrossRefGoogle Scholar
- 27.Lew K, Ng T, Tan M, Tan S, Lew E, Ling L et al (2015) Safety and clinical outcomes of carbapenem de-escalation as part of an antimicrobial stewardship program in an ESBL-endemic setting. J Antimicrob Chemother 70:1219–1225Google Scholar
- 28.Teng CB, Ng TM, Tan MW, Tan SH, Tay M, Lim SF et al (2015) Safety and effectiveness of improving carbapenem use via prospective review and feedback in a multidisciplinary antimicrobial stewardship programme. Ann Acad Med Singap 44(1):19–25Google Scholar
- 35.Davey P, Brown E, Charani E, Fenelon L, Gould IM, Holmes A et al (2013) Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev (4):CD003543. https://doi.org/10.1002/14651858.CD003543.pub3
- 39.Robson SE, Cockburn A, Sneddon J, Mohana A, Bennie M, Mullen AB et al (2018) Optimizing carbapenem use through a national quality improvement programme. J Antimicrob Chemother 73(8):2223–2230. https://doi.org/10.1093/jac/dky171